Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it had net income ...
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical firm with a market capitalization of $119.87 billion, announced today a 2.6% increase in its quarterly cash dividend.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released o ...
Gilead Sciences Inc. sees 2025 earnings rising faster than Wall Street expected after a big fourth-quarter beat highlighted ...
Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.
9d
Hosted on MSNGilead Sciences Stock: Is Wall Street Bullish or Bearish?With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...
Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the development and commercialization of innovative therapies for diseases such ...
Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results